Advanced Cell Technology, Inc.  

(Public, OTCMKTS:ACTC)   Watch this stock  
Find more results for OTC:ACTC
0.0637
+0.0009 (1.43%)
Apr 17 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.06 - 0.07
52 week 0.05 - 0.10
Open 0.07
Vol / Avg. 7.24M/13.11M
Mkt cap 176.89M
P/E     -
Div/yield     -
EPS -0.01
Shares 2.78B
Beta 0.57
Inst. own 0%
Feb 11, 2014
Advanced Cell Technology, Inc. at Biotechnology Industry Organization CEO & Investor Conference
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -31144.52% -13788.28%
Operating margin -30493.34% -13394.54%
EBITD margin - -10394.14%
Return on average assets -861.22% -500.18%
Return on average equity - -
Employees 38 -
CDP Score - -

Address

33 LOCKE DRIVE
MARLBOROUGH, MA 1752
United States - Map
+1-508-7561212 (Phone)
+1-310-5760662 (Fax)

Website links

Description

Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. The Company has acquired, developed and maintained a portfolio of patents and patent applications that forms the base for its research and development efforts in the area of embryonic and adult stem cell research. The Company�s emerging field of treatment called regenerative medicine or cell therapy refers to treatments that are founded on the concept of producing new cells to replace malfunctioning or damaged cells as a vehicle to treat disease and injury. It focuses on the development of effective methods to generate replacement cells from both human embryonic and adult stem cells. In September 2011, it received approval from U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct an SMD clinical trial in the United Kingdom.

Officers and directors

Michael T. Heffernan Chairman of the Board
Age: 49
Edward H. Myles CPA Interim President, Chief Financial Officer, Executive Vice President - Corporate Development
Age: 42
Eddy Anglade MD Executive Vice President - Clinical Development
Robert P. Lanza M.D. Chief Scientific Officer
Age: 57
Robert S. Langer Sc.D. Independent Director
Age: 65
Zohar Loshitzer Independent Director
Age: 56
Gregory D. Perry Independent Director
Age: 53
Alan C. Shapiro Ph.D. Independent Director
Age: 68